WVU medicine is conducting a trial to combat weight gain after patients stop taking GLP-1 drugs such as Ozempic. Officials ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Flowers has documented for several quarters a consumer shift away from traditional loaves toward more “differentiated and premium items” .

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

Their relationship is still going strong. Patrick Mahomes and Travis Kelce said that it was 'a great honor' for the president ...

They're known to aid in blood sugar control and, now, weight loss — however, according to a sweeping new study, the popular ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...